PMID- 21835078
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20211020
IS  - 1469-8161 (Electronic)
IS  - 0031-1820 (Print)
IS  - 0031-1820 (Linking)
VI  - 138
IP  - 12
DP  - 2011 Oct
TI  - Drug resistance maps to guide intermittent preventive treatment of malaria in 
      African infants.
PG  - 1469-79
LID - 10.1017/S0031182011000746 [doi]
AB  - Intermittent preventive treatment of infants (IPTi) with sulphadoxine 
      pyrimethamine (SP) is recommended as an additional malaria control intervention 
      in high transmission areas of sub-Saharan Africa, provided its protective 
      efficacy is not compromised by SP resistance. A significant obstacle in 
      implementing SP-IPTi, is in establishing the degree of resistance in an area. 
      Since SP monotherapy is discontinued, no contemporary measures of in vivo 
      efficacy can be made, so the World Health Organisation has recommended a cut-off 
      based upon molecular markers, stating that SP-IPTi should not be implemented when 
      the prevalence of the dhps 540E mutation among infections exceeds 50%. We created 
      a geo-referenced database of SP resistance markers in Africa from published 
      literature. By selecting surveys of malaria infected blood samples conducted 
      since 2004 we have mapped the contemporary prevalence of dhps 540E. Additional 
      maps are freely available in interactive form at 
      http://www.drugresistancemaps.org/ipti/. Eight countries in East Africa are 
      classified as unsuitable for SP-IPTi when data are considered at a national 
      level. Fourteen countries in Central and West Africa were classified as suitable 
      while seven countries had no available contemporary data to guide policy. There 
      are clear deficiencies in molecular surveillance data coverage. We discuss 
      requirements for ongoing surveillance of SP resistance markers in support of the 
      use of SP-IPTi.
FAU - Naidoo, Inbarani
AU  - Naidoo I
AD  - London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, 
      UK.
FAU - Roper, Cally
AU  - Roper C
LA  - eng
GR  - Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110811
PL  - England
TA  - Parasitology
JT  - Parasitology
JID - 0401121
RN  - 0 (Antimalarials)
RN  - 0 (Drug Combinations)
RN  - 37338-39-9 (fanasil, pyrimethamine drug combination)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)
RN  - EC 2.5.1.15 (Dihydropteroate Synthase)
RN  - Z3614QOX8W (Pyrimethamine)
SB  - IM
MH  - Africa/epidemiology
MH  - Antimalarials/pharmacology/*therapeutic use
MH  - Dihydropteroate Synthase/*genetics
MH  - Drug Combinations
MH  - Drug Resistance/genetics
MH  - Humans
MH  - Infant
MH  - Malaria/drug therapy/epidemiology/genetics/*prevention & control
MH  - Mutation/drug effects
MH  - Plasmodium/drug effects/*genetics
MH  - Prevalence
MH  - Pyrimethamine/pharmacology/*therapeutic use
MH  - Sulfadoxine/pharmacology/*therapeutic use
MH  - Tetrahydrofolate Dehydrogenase/*genetics
PMC - PMC3178874
EDAT- 2011/08/13 06:00
MHDA- 2014/01/22 06:00
CRDT- 2011/08/13 06:00
PHST- 2011/08/13 06:00 [entrez]
PHST- 2011/08/13 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - S0031182011000746 [pii]
AID - 00074 [pii]
AID - 10.1017/S0031182011000746 [doi]
PST - ppublish
SO  - Parasitology. 2011 Oct;138(12):1469-79. doi: 10.1017/S0031182011000746. Epub 2011 
      Aug 11.